NCT06627309 2026-03-09
Rapid dFLC Response Predict CHR in AL Amyloidosis
Peking University People's Hospital
Recruiting
Clinical Trials
21 trialsNCT07200583 2025-11-18
PAIA-Haplo
Fujian Medical University
Completed
NCT07206810 2025-10-03
A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Completed
NCT05163405 2025-08-22
Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.
Odense University Hospital
Completed
NCT02555839 2025-03-28
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
Celgene
Completed
NCT06284395 2024-10-02
Two Schemes Response in Multiple Myeloma
Hospital General de Mexico
Recruiting
NCT06012383 2023-08-25
AlvocadeĀ® (Bortezomib) Safety and Effectiveness Study
NanoAlvand
Completed
NCT05218603 2022-09-16
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
PETHEMA Foundation
Unknown
NCT04678089 2022-04-28
Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics
Beijing Chao Yang Hospital
Unknown
NCT03344328 2020-11-12
PREVIB
University Hospital, Clermont-Ferrand
Completed
NCT02976272 2019-07-01
SENSIB
University Hospital, Clermont-Ferrand
Unknown
NCT02026505 2019-03-13
Evaluation of Cardiotoxic Effects of Bortezomib
Oregon Health and Science University
Completed
NCT02797041 2016-06-14
REBOUND
IRCCS Centro di Riferimento Oncologico della Basilicata
Unknown
NCT02474563 2015-06-30
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
Janssen Korea, Ltd., Korea
Completed
NCT00440479 2015-04-16
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
Janssen-Cilag B.V.
Completed
NCT01021592 2014-12-23
Quality of Life in Multiple Myeloma Patients Treated With Bortezomib
Janssen Korea, Ltd., Korea
Completed
NCT01026701 2014-04-28
Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.
Janssen Korea, Ltd., Korea
Completed
NCT00440765 2014-01-14
VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands
Janssen-Cilag B.V.
Completed
NCT00440635 2013-04-16
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
Janssen-Cilag International NV
Completed
NCT01030302 2013-03-08
A Retreatment Study With Bortezomib for Multiple Myeloma
Janssen Korea, Ltd., Korea
Completed
NCT01005628 2013-02-20
Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)
Janssen Korea, Ltd., Korea
Completed